Trial · NCT00413777
Results by group318
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 318
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Safety Assessments Based on Vital Signs, Electrocardiogram (ECG's), Clinical Laboratory Tests, Physical Examinations Are Reported as Adverse Events (AEs) Upon Study Physician Discretion. | Tolvaptan 45+15 mg | Participants with serious TEAEs | 3 | participants | |
| Safety Assessments Based on Vital Signs, Electrocardiogram (ECG's), Clinical Laboratory Tests, Physical Examinations Are Reported as Adverse Events (AEs) Upon Study Physician Discretion. | Tolvaptan 60+30 mg | Participants with serious TEAEs | 8 | participants | |
| Safety Assessments Based on Vital Signs, Electrocardiogram (ECG's), Clinical Laboratory Tests, Physical Examinations Are Reported as Adverse Events (AEs) Upon Study Physician Discretion. | Tolvaptan 45+15 mg | Participants with severe TEAEs | 6 | participants | |
| Safety Assessments Based on Vital Signs, Electrocardiogram (ECG's), Clinical Laboratory Tests, Physical Examinations Are Reported as Adverse Events (AEs) Upon Study Physician Discretion. | Tolvaptan 60+30 mg | Participants with severe TEAEs | 10 | participants | |
| Safety Assessments Based on Vital Signs, Electrocardiogram (ECG's), Clinical Laboratory Tests, Physical Examinations Are Reported as Adverse Events (AEs) Upon Study Physician Discretion. | Tolvaptan 45+15 mg | Participants discontinued due to AEs | 3 | participants | |
| Safety Assessments Based on Vital Signs, Electrocardiogram (ECG's), Clinical Laboratory Tests, Physical Examinations Are Reported as Adverse Events (AEs) Upon Study Physician Discretion. | Tolvaptan 60+30 mg | Participants discontinued due to AEs | 1 | participants | |
| Mean Change From Baseline in Trough Urine Osmolality at Steady State Prior to First Daily Dose. | Tolvaptan 45+15 mg | Month 2 (N= 21, 22) | -274.10 | Standard Deviation 223.14 | mOsm/kg |
| Mean Change From Baseline in Trough Urine Osmolality at Steady State Prior to First Daily Dose. | Tolvaptan 60+30 mg | Month 2 (N= 21, 22) | -228.00 | Standard Deviation 238.19 | mOsm/kg |
| Mean Change From Baseline in Trough Urine Osmolality at Steady State Prior to First Daily Dose. | Tolvaptan 45+15 mg | Month 6 (N= 19, 23) | -288.42 | Standard Deviation 219.55 | mOsm/kg |
| Mean Change From Baseline in Trough Urine Osmolality at Steady State Prior to First Daily Dose. | Tolvaptan 60+30 mg | Month 6 (N= 19, 23) | -263.78 | Standard Deviation 221.05 | mOsm/kg |
| Mean Change From Baseline in Trough Urine Osmolality at Steady State Prior to First Daily Dose. | Tolvaptan 45+15 mg | Month 12 (N= 17, 21) | -227.29 | Standard Deviation 226.63 | mOsm/kg |
| Mean Change From Baseline in Trough Urine Osmolality at Steady State Prior to First Daily Dose. | Tolvaptan 60+30 mg | Month 12 (N= 17, 21) | -178.43 | Standard Deviation 228.43 | mOsm/kg |
| Mean Change From Baseline in Trough Urine Osmolality at Steady State Prior to First Daily Dose. | Tolvaptan 45+15 mg | Month 24 (N= 18, 20) | -170.17 | Standard Deviation 272.21 | mOsm/kg |
| Mean Change From Baseline in Trough Urine Osmolality at Steady State Prior to First Daily Dose. | Tolvaptan 60+30 mg | Month 24 (N= 18, 20) | -189.75 | Standard Deviation 229.33 | mOsm/kg |
| Mean Change From Baseline in Trough Urine Osmolality at Steady State Prior to First Daily Dose. | Tolvaptan 45+15 mg | Month 36 (N= 18, 21) | -222.50 | Standard Deviation 229.91 | mOsm/kg |
| Mean Change From Baseline in Trough Urine Osmolality at Steady State Prior to First Daily Dose. | Tolvaptan 60+30 mg | Month 36 (N= 18, 21) | -208.90 | Standard Deviation 194.19 | mOsm/kg |
| Mean Change From Baseline in Trough Urine Osmolality at Steady State Prior to Second Daily Dose. | Tolvaptan 45+15 mg | Month 2 (N= 21, 21) | -263.95 | Standard Deviation 220.40 | mOsm/kg |
| Mean Change From Baseline in Trough Urine Osmolality at Steady State Prior to Second Daily Dose. | Tolvaptan 60+30 mg | Month 2 (N= 21, 21) | -298.71 | Standard Deviation 257.53 | mOsm/kg |
| Mean Change From Baseline in Trough Urine Osmolality at Steady State Prior to Second Daily Dose. | Tolvaptan 45+15 mg | Month 6 (N= 19, 23) | -321.78 | Standard Deviation 242.53 | mOsm/kg |
| Mean Change From Baseline in Trough Urine Osmolality at Steady State Prior to Second Daily Dose. | Tolvaptan 60+30 mg | Month 6 (N= 19, 23) | -294.13 | Standard Deviation 215.95 | mOsm/kg |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00413777/results